GEN-MKT-18-7897-A
Sep 15, 2020 | Biopharma, Blogs, Echo® MS+ system, Pharma | 0 comments
How fast is fast?
Cheetahs. Usain Bolt. Tachyons. The Echo® MS system.
They’re all fast. REALLY fast. In fact, they’re the fastest in their categories: the fastest land mammal, the fastest human sprinter, the fastest subatomic particle and the fastest high-throughput mass spectrometry sampling system.
The Echo® MS system sets a new speed record for quantitative mass spec analysis with the ability to analyze up to 3 samples per second. That’s up to 50 times faster than conventional LC-MS. 50 times! But the big difference here is that there is no LC.
Instead, the Echo® MS system uses Acoustic Droplet Ejection (ADE) to basically “vibrate” a nanoliter-sized droplet of sample directly out of the solution from a microwell plate into an Open Port Interface (OPI). Solvents within the OPI sweep the sample directly to the electrospray source of the MS system. Because of the dilution effects that occur within the OPI, matrix suppression effects are essentially eliminated, making for a very clean and sensitive analysis. As a result, most small molecules in drug discovery reach single-digit nanomolar-level sensitivity. And time-consuming sample preparation steps are no longer necessary.
Because there is no LC, contact areas required for conventional LC-MS, such as injection needles and loops, are removed. Sample introduction is achieved through a contactless interaction of the ADE with the OPI. Without these contact areas, carryover from sample to sample is virtually eliminated, even when moving between concentration extremes. Additionally, the lack of LC means the elimination of chromatographic run times as well as LC method development time.
When compared to LC-MS, Chang Liu from SCIEX R&D sums it up nicely:
“The Echo® MS System is much faster, consumes much less sample, requires much less effort for sample preparation or method development and we could eliminate the carryover problems.”1
To increase throughput even more, the hardware and software of the Echo® MS System was designed for easy assimilation into high-throughput environments. Standard robot arms can easily transfer plates to and from the system.
With no sample preparation, no LC method development, no LC run time, incredibly fast sampling and high-throughput design considerations, the Echo® MS System is already changing the field of high-throughput analysis within drug discovery.
Don’t play by the rules. Change the game. And finish your work in record time. To learn more about this game-changing innovation and how you too can “Run Fast,” visit the Echo® MS System website for more information and see how fast is really fast.
References:
This blog is part 1 of a 3-part series on the Echo® MS System. Read part 2 (“Scale it up! The Echo® MS System delivers unprecedented levels of productivity”) and part 3 (“The Echo® MS System: Is it reproducible? Yes… yes… yes!”).
RUO-MKT-18-12281-A Echo® and Echo® MS are trademarks or registered trademarks of Labcyte Inc. in the United States and other countries, being used under license by SCIEX.
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network